Boostrix vaccine approved for adults

BOOSTRIX (Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine) by GlaxoSmithKline
BOOSTRIX (Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine) by GlaxoSmithKline

GlaxoSmithKline's combination vaccine Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed [Tdap]) has been approved by the FDA for the immunization of adults 19–64 years of age against tetanus, diphtheria and pertussis (whooping cough). This approval is based on data from two clinical studies demonstrating the overall safety and immunogenicity of Boostrix in providing booster protection in nearly 3000 adults.

Boostrix was already indicated as a booster vaccination for the preventions of diphtheria, tetanus, and pertussis in patients 10–18 years of age.

For more information call (888) 825-5249 or visit www.boostrix.com.